Part 1 - Background

Your chance to shape an industry research project
Thank you for your interest in taking part in this UK-wide online survey of individuals with inflammatory bowel disease (IBD). This survey is for anyone over the age of 18 who has been diagnosed with Crohn’s disease (CD) or ulcerative colitis (UC). We invite patients irrespective of age, gender, ethnicity, and extent of their disease to take part. Your responses will help guide the development of a new test aiming to improve the clinical care of CD and UC.
The survey should take approximately 15 minutes to complete. However, you can leave the survey at any point and return later to complete. The survey will close on the 31st of January 2022.
Who is conducting this survey?
AlphaBiomics ( is a UK-based healthcare company founded in 2018. Our aim is to improve and personalise the clinical care of individuals diagnosed with chronic diseases such as IBD. This survey has been designed by AlphaBiomics with support from our Patient and Public Involvement partners and our advisory group of individuals with lived experience with IBD.
Why are we doing this survey?
AlphaBiomics is developing a test to improve how biologic drugs are chosen for patients living with CD or UC. The test will provide patients, doctors and IBD nurses with new information so that they know if biologic drugs will work for a patient before treatment begins. We would like to collect your thoughts about this test and understand whether you believe the test would improve your care.
What are the benefits of taking part?
Your participation in this survey will help shape a new diagnostic product and improve care pathways for people like you in the future. A summary of the survey results will be published on AlphaBiomics’ website where you will be able to see them.
How we are handling your data
We do not collect identifying information such as your name, email address or IP address. Your responses will be anonymous and will be stored securely by AlphaBiomics.
Please contact if you have any questions regarding this survey.
3% of survey complete.